Skip to main content
. 2021 Apr 9;13:42. doi: 10.1186/s13098-021-00654-3

Table 1.

Efficacy of the flash glucose monitoring system versus self-monitoring of blood glucose in the REPLACE open-label randomized controlled trial and extension study in patients with type 2 diabetes mellitus

Randomized controlled trial Outcome (FGMS vs. SMBG) [N = 149 vs. N = 75] P value
Overall population (6 months) Mean change from baseline in HbA1c:  − 0.29 ± 0.07 vs. − 0.31 ± 0.09% P = 0.8222
Subgroup analyses (6 months)
 Age
  < 65 years Mean change from baseline in HbA1c: − 0.53 ± 0.09 vs. − 0.20 ± 0.12% P = 0.0301
  ≥ 65 years  − 0.05 ± 0.10 vs. − 0.49 ± 0.13% P = 0.0081
 Time spent in hypoglycemia [h/day]: mean change from baseline
  Glucose < 70 mg/dL Between-group difference:  − 43% [mean ± SE − 0.47 ± 0.13] P = 0.0006
  Glucose < 55 mg/dL  − 53% [− 0.22 ± 0.07] P = 0.0014
  Glucose < 45 mg/dL  − 64% [− 0.14 ± 0.04] P = 0.0013
 Frequency of hypoglycemic events [per day]: mean change from baseline
  Glucose < 70 mg/dL Between-group difference:  − 28% [mean ± SE − 0.16 ± 0.07] P = 0.0164
  Glucose < 55 mg/dL  − 44% [− 0.12 ± 0.04] P = 0.0017
  Glucose < 45 mg/dL  − 49% [− 0.06 ± 0.02] P = 0.0098
 AUC [h/day × mg/dL]
  Glucose < 70 mg/dL Between-group difference:  − 51% [mean ± SE − 7.80 ± 2.20] P = 0.0005
  Glucose < 55 mg/dL  − 60% [− 2.51 ± 0.76] P = 0.0012
  Glucose < 45 mg/dL  − 67% [− 0.70 ± 0.22] P = 0.0015
Extension phase Outcome (FGMS vs. baseline) [N = 139]
Subgroup analyses (12 months)
 Time spent in hypoglycemia [h/day]
  Glucose < 70 mg/dL Mean change from baseline (start of treatment phase):  − 50% [mean ± SD − 0.70 ± 1.85] P = 0.0002
  Glucose < 55 mg/dL  − 62% [− 0.40 ± 1.09] P = 0.0002
  Glucose < 45 mg/dL  − 67% [− 0.23 ± 0.73] P = 0.0013
 Frequency of hypoglycemic events [per day]
  Glucose < 70 mg/dL Mean change from baseline (start of treatment phase):  − 41% [mean ± SD − 0.27 ± 0.67] P < 0.0001
  Glucose < 55 mg/dL  − 56% [− 0.20 ± 0.49] P < 0.0001
  Glucose < 45 mg/dL  − 62% [− 0.13 ± 0.35] P = 0.0002
 AUC [h/day × mg/dL]
  Glucose < 70 mg/dL Mean change from baseline (start of treatment phase):  − 58% (mean ± SD − 12.73 ± 34.53] P = 0.0002
  Glucose < 55 mg/dL  − 65% [− 4.28 ± 12.76] P = 0.0007
  Glucose < 45 mg/dL  − 69% [− 1.12 ± 3.67] P = 0.0021

Data from [8, 9]

BG levels are presented as mg/dL, which can be converted to mmol/L by multiplying values by 0.05551

AUC area under the concentration–time curve, FGMS flash glucose monitoring system, HbA1c glycosylated haemoglobin, SMBG self-monitoring of blood glucose